Airborne transmission of SARS-CoV-2 via aerosols.


Journal

Reviews in medical virology
ISSN: 1099-1654
Titre abrégé: Rev Med Virol
Pays: England
ID NLM: 9112448

Informations de publication

Date de publication:
05 2021
Historique:
revised: 08 10 2020
received: 01 09 2020
accepted: 10 10 2020
pubmed: 27 10 2020
medline: 1 6 2021
entrez: 26 10 2020
Statut: ppublish

Résumé

A key consideration in the Covid-19 pandemic is the dominant modes of transmission of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. The objective of this review was to synthesise the evidence for the potential airborne transmission of SARS-CoV-2 via aerosols. Systematic literature searches were conducted in PubMed, Embase, Europe PMC and National Health Service UK evidence up to 27 July 2020. A protocol was published and Cochrane guidance for rapid review methodology was adhered to throughout. Twenty-eight studies were identified. Seven out of eight epidemiological studies suggest aerosol transmission may occur, with enclosed environments and poor ventilation noted as possible contextual factors. Ten of the 16 air sampling studies detected SARS-CoV-2 ribonucleic acid; however, only three of these studies attempted to culture the virus with one being successful in a limited number of samples. Two of four virological studies using artificially generated aerosols indicated that SARS-CoV-2 is viable in aerosols. The results of this review indicate there is inconclusive evidence regarding the viability and infectivity of SARS-CoV-2 in aerosols. Epidemiological studies suggest possible transmission, with contextual factors noted. Viral particles have been detected in air sampling studies with some evidence of clinical infectivity, and virological studies indicate these particles may represent live virus, adding further plausibility. However, there is uncertainty as to the nature and impact of aerosol transmission of SARS-CoV-2, and its relative contribution to the Covid-19 pandemic compared with other modes of transmission.

Identifiants

pubmed: 33105071
doi: 10.1002/rmv.2184
pmc: PMC7645866
doi:

Substances chimiques

Aerosols 0
RNA, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2184

Subventions

Organisme : Health Research Board
ID : HRB-CICER-2016-1871
Pays : Ireland

Informations de copyright

© 2020 John Wiley & Sons Ltd.

Références

Emerg Infect Dis. 2006 Nov;12(11):1657-62
pubmed: 17283614
Emerg Infect Dis. 2020 Sep;26(9):
pubmed: 32568661
Influenza Other Respir Viruses. 2020 Nov;14(6):688-699
pubmed: 32578948
Proc Natl Acad Sci U S A. 2020 Jun 30;117(26):14857-14863
pubmed: 32527856
Emerg Infect Dis. 2020 Jun;26(6):1343-1345
pubmed: 32163030
J Infect Dis. 2020 Jul 23;222(4):564-571
pubmed: 32525979
MMWR Morb Mortal Wkly Rep. 2020 May 15;69(19):606-610
pubmed: 32407303
Indoor Air. 2021 Mar;31(2):314-323
pubmed: 32979298
Curr Opin Virol. 2018 Feb;28:142-151
pubmed: 29452994
J Infect. 2011 Jan;62(1):1-13
pubmed: 21094184
JAMA Netw Open. 2020 Jul 1;3(7):e2013807
pubmed: 32716517
Emerg Infect Dis. 2020 Jul;26(7):1583-1591
pubmed: 32275497
Mater Today Phys. 2020 Dec;15:100249
pubmed: 34173438
J Infect Dis. 2020 Sep 1;222(7):1098-1102
pubmed: 32691828
Int J Infect Dis. 2020 Nov;100:476-482
pubmed: 32949774
J R Soc Interface. 2009 Dec 6;6 Suppl 6:S783-90
pubmed: 19773292
Clin Infect Dis. 2020 Dec 3;71(9):2311-2313
pubmed: 32628269
Clin Infect Dis. 2021 Oct 5;73(7):e1870-e1877
pubmed: 32634826
Sci Total Environ. 2020 Jul 10;725:138401
pubmed: 32283308
Nature. 2020 Jun;582(7813):557-560
pubmed: 32340022
BMC Infect Dis. 2019 Jan 31;19(1):101
pubmed: 30704406
Environ Int. 2020 Dec;145:106112
pubmed: 32927282
Microbiol Mol Biol Rev. 2008 Sep;72(3):413-44
pubmed: 18772283
Infect Control Hosp Epidemiol. 2021 Sep;42(9):1046-1052
pubmed: 32618530
J Virol. 2010 Nov;84(21):11255-63
pubmed: 20719951
Sci Total Environ. 2020 Nov 10;742:140540
pubmed: 32619843
JAMA. 2020 Aug 4;324(5):441-442
pubmed: 32749495
Lancet Infect Dis. 2017 Dec;17(12):e420-e428
pubmed: 28757186
JAMA. 2020 Apr 28;323(16):1610-1612
pubmed: 32129805
Infect Control Hosp Epidemiol. 2020 Nov;41(11):1258-1265
pubmed: 32507114
Nat Commun. 2020 May 29;11(1):2800
pubmed: 32472043
N Engl J Med. 2020 Apr 16;382(16):1564-1567
pubmed: 32182409
Int J Environ Res Public Health. 2020 Dec 26;18(1):
pubmed: 33375308
Ann Intern Med. 2020 Dec 15;173(12):974-980
pubmed: 32870707

Auteurs

Laura Comber (L)

Health Technology Assessment Directorate, Health Information and Quality Authority, Dublin, Ireland.

Eamon O Murchu (E)

Health Technology Assessment Directorate, Health Information and Quality Authority, Dublin, Ireland.

Linda Drummond (L)

Health Technology Assessment Directorate, Health Information and Quality Authority, Dublin, Ireland.

Paul G Carty (PG)

Health Technology Assessment Directorate, Health Information and Quality Authority, Dublin, Ireland.

Kieran A Walsh (KA)

Health Technology Assessment Directorate, Health Information and Quality Authority, Dublin, Ireland.

Cillian F De Gascun (CF)

National Virus Reference Laboratory, University College Dublin, Dublin, Ireland.

Máire A Connolly (MA)

School of Medicine, National University of Ireland Galway, Galway, Ireland.

Susan M Smith (SM)

Department of General Practice, Health Research Board Centre for Primary Care Research, Royal College of Surgeons in Ireland, Dublin, Ireland.

Michelle O'Neill (M)

Health Technology Assessment Directorate, Health Information and Quality Authority, Dublin, Ireland.

Máirín Ryan (M)

Health Technology Assessment Directorate, Health Information and Quality Authority, Dublin, Ireland.
Department of Pharmacology & Therapeutics, Trinity College Dublin, Dublin, Ireland.

Patricia Harrington (P)

Health Technology Assessment Directorate, Health Information and Quality Authority, Dublin, Ireland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH